OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
wccc完成签到,获得积分20
2秒前
3秒前
芒果个冉冉完成签到,获得积分10
3秒前
YZZ发布了新的文献求助10
5秒前
灵剑山完成签到 ,获得积分10
6秒前
crazyant完成签到,获得积分20
6秒前
乔ovo发布了新的文献求助10
6秒前
侯佳君完成签到,获得积分20
6秒前
7秒前
7秒前
8秒前
华仔应助VickyS采纳,获得10
9秒前
LFH发布了新的文献求助10
9秒前
侯佳君发布了新的文献求助10
9秒前
cc66完成签到 ,获得积分10
10秒前
crazyant发布了新的文献求助10
11秒前
铁墙完成签到,获得积分10
12秒前
13秒前
Leonard完成签到,获得积分10
13秒前
TRTHHRTZ发布了新的文献求助10
14秒前
共享精神应助CHEN采纳,获得10
14秒前
16秒前
桐桐应助zzz采纳,获得10
17秒前
今天只做一件事完成签到,获得积分0
18秒前
18秒前
懵懂的雪糕完成签到 ,获得积分10
18秒前
19秒前
kitty发布了新的文献求助10
20秒前
杨小欣发布了新的文献求助10
22秒前
linger发布了新的文献求助10
22秒前
周周发布了新的文献求助10
22秒前
cc137完成签到 ,获得积分10
22秒前
23秒前
忧郁的忆南完成签到 ,获得积分10
24秒前
李喜喜发布了新的文献求助10
24秒前
Starwalker应助A溶大美噶采纳,获得20
26秒前
朱晓芸完成签到,获得积分10
26秒前
张zi完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Cronologia da história de Macau 5000
Braunwald’s Heart Disease, 2 Vol Set A Textbook of Cardiovascular Medicine 13th Edition 1000
Petrology and Plate Tectonics 800
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
Handbook Of Synthetic Methodologies And Protocols Of Nanomaterials 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 光电子学 物理化学 电极 基因 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 6997020
求助须知:如何正确求助?哪些是违规求助? 8672903
关于积分的说明 18390326
捐赠科研通 6471303
什么是DOI,文献DOI怎么找? 3099198
关于科研通互助平台的介绍 2162277
邀请新用户注册赠送积分活动 2075590